TBThomas Braulke

Thomas Braulke

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Thomas Braulke has a total of 42 co-authors. Here are the top co-authors by number of shared publications:

  • Kurt Ullrich

    University Medical Center Hamburg, Hamburg, Germany

    5 shared publications
  • Nicole Muschol

    Department of Biochemistry, Children's Hospital, University Hospital Hamburg Eppendorf, Hamburg, Germany

    3 shared publications
  • Michael Cantz

    Institute of Pathochemistry and Neurochemistry, University of Heidelberg, Heidelberg, Germany

    2 shared publications
  • Stephan Storch

    Section Biochemistry, Children's Hospital, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany

    2 shared publications
  • Stephan Tiede

    Department of Biochemistry, Children's Hospital, University Hospital Hamburg Eppendorf, Hamburg, Germany

    2 shared publications
  • Aija Kyttdlld

    National Public Health Institute, and Institute for Molecular Medicine Finland, Helsinki, Finland

    1 shared publication

Latest Publications

  • 124. Retention of lysosomal protein CLN5 in the endoplasmic reticulum causes neuronal ceroid lipofuscinosis in Asian sibship

    by Angela Schulz, Anne-Helene Lebrun, Stephan Storch, R∣Schendorf Franz, Mia-Lisa Schmiedt, Aija Kyttdlld, Sara E. Mole, Claudia Kitzm∣Ller, Leena D. Mewasingh, Volker Boda, et al.

  • Accumulation of bis(monoacylglycero)phosphate and gangliosides in mouse models of neuronal ceroid lipofuscinosis

    by Sabrina Jabs, Arne Quitsch, Reijo Käkelä, Bettina Koch, Jaana Tyynelä, Helmut Brade, Markus Glatzel, Steven Walkley, Paul Saftig, Marie T. Vanier, et al.

    The neuronal ceroid lipofuscinoses comprise a group of inherited severe neurodegenerative lysosomal disorders characterized by lysosomal dysfunction and massive accumulation of fluorescent lipopigments and aggregated proteins. To examine the role of lipids in neurodegenerative processes of these diseases, we analysed phospho‐ and glycolipids in the brains of ctsd−/− and nclf mice, disease models of cathepsin D and CLN6 deficiency, respectively. Both ctsd−/− and nclf mice exhibited increased levels of GM2 and GM3 gangliosides. Immunohistochemically GM2 and GM3 staining was found preferentially in neurons and glial cells, respectively, of ctsd−/− mice. Of particular note, a 20‐fold elevation of the unusual lysophospholipid bis(monoacylglycero)phosphate was specifically detected in the brain of ctsd−/− mice accompanied with sporadic accumulation of unesterified cholesterol in distinct cells. The impaired processing of the sphingolipid activator protein precursor, an in vitro cathepsin D substrate, in the brain of ctsd−/− mice may provide the mechanistic link to the storage of lipids. These studies show for the first time that cathepsin D regulates the lysosomal phospho‐ and glycosphingolipid metabolism suggesting that defects in the composition, trafficking and/or recycling of membrane components along the late endocytic pathway may be critical for the pathogenesis of early onset neuronal ceroid lipofuscinoses.


  • Endothelial Effects of 3-Hydroxyglutaric Acid: Implications for Glutaric Aciduria Type I

    by Chris Mühlhausen, Nicola Ott, Fariba Chalajour, Derya Tilki, Folke Freudenberg, Mona Shahhossini, Joachim Thiem, Kurt Ullrich, Thomas Braulke, Süleyman Ergün


  • Open Access

    Missense mutations in N‐acetylglucosamine‐1‐phosphotransferase α/β subunit gene in a patient with mucolipidosis III and a mild clinical phenotype

    by Stephan Tiede, Nicole Muschol, Gert Reutter, Michael Cantz, Kurt Ullrich, Thomas Braulke

    Mucolipidosis type III (ML III, pseudo‐Hurler polydystrophy), an autosomal recessive inherited disorder of lysosomal enzyme targeting is due to a defective N‐acetylglucosamine 1‐phosphotransferase (phosphotransferase) activity and leads to the impaired formation of mannose 6‐phosphate markers in soluble lysosomal enzymes followed by their increased excretion into the serum. Mutations in the phosphotransferase γ subunit gene (GNPTAG) have been reported to be responsible for ML III. Here we report on a 14‐year‐old adolescent with a mild clinical phenotype of ML III. He presented with progressive joint stiffness and swelling. Urinary oligosaccharide and mucopolysaccharide excretion was normal. Lysosomal enzyme activities were significantly elevated in the serum and decreased in cultured fibroblasts. Impaired trafficking of the lysosomal protease cathepsin D (CtsD) was confirmed by metabolic labeling of the patient's fibroblasts. Neither mutations in the GNPTAG gene nor alterations in the GNPTAG mRNA level were detected whereas the steady state concentration of the 97 kDa GNPTAG dimer was reduced. Most importantly, the patient is homozygous for a pathogenic nucleotide substitution and a polymorphism in the phosphotransferase α/β subunit gene (GNPTA). The data indicate that defects in genes other than GNPTAG can be linked to ML III contributing to the variability of the phenotype.


  • Open Access

    A novel mutation in UDP-N-acetylglucosamine-1-phosphotransferase gamma subunit (GNPTAG) in two siblings with mucolipidosis type III alters a used glycosylation site

    by Stephan Tiede, Michael Cantz, Annick Raas-Rothschild, Nicole Muschol, Friederike Bürger, Kurt Ullrich, Thomas Braulke

    The N‐acetylglucosaminyl‐1‐phosphotransferase (termed phosphotransferase) catalyzes the initial step in the formation of mannose 6‐phosphate (M6P) residues required for the efficient transport of soluble lysosomal enzymes. The phosphotransferase is a multisubunit enzyme composed of three subunits (α2β2γ2) that are products of two genes. The gene encoding the γ‐subunit (GNPTAG) appears to be defective in patients with mucolipidosis type III (ML III). We have analyzed the GNPTAG gene in two siblings with ML III showing elevated activities of several lysosomal enzymes in cultured fibroblasts serum and diminished activities in cultured fibroblasts. Immunoprecipitation of metabolically labeled cathepsin D (CtsD) from fibroblasts revealed that the sorting/transport of this lysosomal protease was affected. Addition of ammonium chloride inhibiting pH‐dependent processes, such as the CtsD‐M6P receptor interaction, indicated that 15 to 20% of the newly synthesized CtsD is transported in ML III fibroblasts in an M6P‐dependent manner. By direct sequencing a novel homozygous mutation, c.347_349delACA (p.Asn116del), was identified affecting a potential N‐linked glycosylation site. Western blot analysis of extracts from control fibroblasts detect a 97 kDa glycosylated dimer whereas ML III cells contain a GNPTAG dimer of reduced molecular mass. These data suggest that the loss of the used glycosylation site in the gamma subunit may affect the intracellular localization of GNPTAG and the overall efficiency of M6P formation.


  • Transport, enzymatic activity, and stability of mutant sulfamidase (SGSH) identified in patients with mucopolysaccharidosis type III A

    by Nicole Muschol, Stephan Storch, Diana Ballhausen, Clare Beesley, Jan-Christoph Westermann, Andreas Gal, Kurt Ullrich, John J. Hopwood, Bryan Winchester, Thomas Braulke

    Mucopolysaccharidosis type IIIA (MPSIIIA) is an autosomal recessive lysosomal storage disease caused by mutations in the N‐sulfoglucosamine sulfohydrolase gene (SGSH; encoding sulfamidase, also sulphamidase) leading to the lysosomal accumulation and urinary excretion of heparan sulfate. Considerable variation in the onset and severity of the clinical phenotype is observed. We report here on expression studies of four novel mutations: c.318C>A (p.Ser106Arg), c.488T>C (p.Leu163Pro), c.571G>A (p.Gly191Arg), and c.1207_1209delTAC (p.Tyr403del), and five previously known mutations: c.220C>T (p.Arg74Cys), c.697C>T (p.Arg233X), c.1297C>T (p.Arg433Trp), c.1026dupC (p.Leu343fsX158), and c.1135delG (p.Val379fsX33) identified in MPSIIIA patients. Transient expression of mutant sulfamidases in BHK or CHO cells revealed that all the mutants were enzymatically inactive with the exception of c.318C>A (p.Ser106Arg), which showed 3.3% activity of the expressed wild‐type enzyme. Western blot analysis demonstrated that the amounts of expressed mutant sulfamidases were significantly reduced compared with cells expressing wild type. No polypeptides were immunodetectable in extracts of cells transfected with the cDNA carrying the c.697C>T (p.Arg233X) nonsense mutation. In vitro translation and pulse‐chase experiments showed that rapid degradation rather than a decrease in synthesis is responsible for the low, steady‐state level of the mutant proteins in cells. The amounts of secreted mutant precursor forms, the cellular stability, the proteolytic processing, and data from double‐label immunofluorescence microscopy suggest that the degradation of the majority of newly synthesized c.220C>T (p.Arg74Cys), c.571G>A (p.Gly191Arg), c.1297C>T (p.Arg433Trp), c.1026dupC (p.Leu343fsX158), and c.1135delG (p.Val379fsX33) mutant proteins probably occurs in the ER, whereas c.488T>C (p.Leu163Pro) mutant protein showed instability in the lysosomes. Hum Mutat 23:559–566, 2004.